After demonstrating that AGI-134 treatment of cells in vitro initiates an immunological cascade that ultimately results in the activation of CD8+ T cells against cell-associated antigens, we evaluated the antitumor efficacy of AGI-134 in abscopal models of murine melanoma. This evidence concerns the gene CD8A and melanoma.